TargetRx to Address Critical Sales and Marketing Issues at Key Pharmaceutical Industry Events

Pharmaceutical Sales and Marketing Thought Leader to Offer New Strategies for Successful Product Launches

Horsham, PA - November 29, 2006 - TargetRx President and CEO Mike Luby will deliver the keynote address at the upcoming 5th Annual Pharmaceutical Product Launches Summit, to be held December 5-6, 2006. As a keynote presenter, Luby will discuss the actions a company should take prior to the launch of a new drug in order to maximize brand opportunities.

This conference will feature both pharmaceutical and biotech executives from companies such as AstraZeneca and Endo Pharmaceuticals, who will discuss how pharmaceutical, biotech and specialty pharmas prosper by bringing new drugs to market. The program will cover the latest issues facing product launch teams, including launch readiness, maximizing ROI, pre-launch reimbursement, global launch success and co-promotional launch tactics.

CBI's 5th Annual Pharmaceutical Product Launches Summit
December 5-6, West Conshohocken, Pa.

Conference Co-chair
Keynote Address: Predictive Power: Higher Standards for Product Launches Bring New Strategies for Success, Tuesday, December 5, 2006, 2:05-2:35 p.m.

In addition to serving as the conference co-chair, Luby's keynote address will discuss how new products play an extremely critical role in the health of the pharmaceutical industry and what can be done to improve product launches. With competition rising and so much riding on the success of each launch, the tools to help pharmaceutical companies execute a successful launch should be well-oiled machines but this couldn't be further from the truth. Currently, there is no standard of information to evaluate:

  • Achievable opportunity for a brand post-launch,
  • A brand's readiness to capture that opportunity, or
  • The actions to take prior to launch to ensure greater launch success.

However, this knowledge can be gained by tracking critical factors such as physician awareness, knowledge of the launch product, perceptions relative to other products, how the product addresses unmet needs in the marketplace and anticipated usage of the product when launched. Luby's session will describe both the need and opportunity for pharmaceutical companies to improve the effectiveness of new product launches, minimizing the risks of under-performance and increasing the opportunities for success.

For more information or to register for this event, visit: www.cbinet.com

About TargetRx

TargetRx provides pharmaceutical and biotech companies with unique insight into the true drivers of product choice and adoption for their brands, helping clients to confidently take the actions that will grow their businesses and help patients. Serving the majority of the top 30 pharmaceutical and biotech companies, TargetRx enables clients to significantly improve the launch of new products and indications, physician segmentation and targeting, creation of professional messaging and materials, and sales and marketing execution and effectiveness. All TargetRx solutions are powered by our AdvantageBuilderSM normative database and validated predictive models, created from capturing in-depth physician attitudes on the "four forces" of prescribing - product, payor, promotion and patient - on new launches, marketing campaigns and physician-rep interactions on over 500 pipeline and inline brands and modeling these attitudes against actual prescribing behavior. For more information, visit www.targetrx.com.

Media Contact:

Joe Ford
Phone: 215-444-8722
jford@targetrx.com